Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s137068
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited